The Food and Drug Administration said Monday that a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of ...

The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial fibrillation after ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in nearly $2.4 billion in US sales last year. The US regulator has cleared 2.5mg ...

Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for ...

Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Both doses of Xarelto (10mg and 20mg) were superior to aspirin (100mg) in ...

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States. FDA’s Center for Drug Evaluation and ...

Bayer AG BAYRY and partner J&J JNJ announced data from two late-stage studies, which showed that its blood thinner drug, Xarelto failed to show statistical benefits. These studies were being evaluated ...

The controversy over Xarelto’s approval by the FDA and alleged irregularities in the conduct of the ROCKET-AF clinical trial continue to hang over the heads of Bayer and Janssen (a division of Johnson ...

Bayer and Johnson & Johnson have received a major boost with the news that panellists at the US regulator have recommended approval of the anticoagulant Xarelto, despite concerns over bleeding and ...

The FDA approved the anticoagulant rivaroxaban (Xarelto, Janssen), to reduce the risk for stroke among patients with non-valvular atrial fibrillation (AF). Approval comes after data from the ROCKET-AF ...

(CBS/AP) The FDA moved closer to approving Xarelto (rivaroxaban) for the treatment of a heart condition that raises the risk for stroke when an advisory panel for the agency on Thursday green-lighted ...